



Receipt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No: OXVIG=1A

In re Application of:)	Office of Initial Patent
)	Examination's Customer
Claus OXVIG)	Service Center
)	
Serial No.: 09/983,025)	Art Unit: 1645
)	
Filed: October 22, 2001)	Confirmation No.: 716
)	
For: PREGNANCY-ASSOCIATED)	Washington, D.C.
PLASMA PROTEIN-A2 (PAPP-A2))	February 6, 2002

RECEIVED
FEB 19 2002
TECH CENTER 1600/2906

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

A filing receipt for the above-identified patent application has been issued by the U.S. Patent and Trademark Office (copy attached) and has been found to contain the following error:

The second applicant's middle name has been incorrectly recorded. It currently reads:

Michael Tofl Overgaard, Aarhus C., DENMARK;

It should read:

Michael Toft Overgaard, Aarhus C., DENMARK;

The error appears to have been an error on the part of the Patent and Trademark Office. It is respectfully requested that a corrected filing receipt be issued in this application, correcting the above error.


In re Serial No.097983,025

Since the error was made by the U.S. Patent and Trademark Office, it is believed that no fee is due. However, if additional fees are due for correcting the filing receipt, the Commissioner is hereby authorized to charge them to our deposit account, No. 02-4035.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By



Iver P. Cooper
Registration No. 28,005

IPC:jmb
624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
f:/,h/hoib/oxvigla/ReqCorrectedOFRIPC5feb02.doc




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/983,025	10/22/2001	1645	0.00	OXVIG=1A	11	67	5

BROWDY AND NEIMARK, P.L.L.C.
624 Ninth Street, N.W.
Washington, DC 20001



FILING RECEIPT



OC000000007068152

CONFIRMATION NO. 775

Date Mailed: 11/14/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Claus Oxvig, Viby, DENMARK;
Michael Toft Overgaard, Aarhus C., DENMARK;

Assignment For Published Patent Application

Como Biotech ApS, Aarhus C., DENMARK;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/241,840 10/20/2000

Foreign Applications

DENMARK PA 2000 01571 10/20/2000

If Required, Foreign Filing License Granted 11/14/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Pregnancy-associated plasma protein-A2 (PAPP-A2)

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Continued